// App-Quantinova.ai

P225 2016 HTN : Nox1 or Nox4 Deletion Prevents Type-1 Diabetes-induced Endothelial Dysfunction

Researchers

Presenter

  • Noureddine Idris-Khodja

Principal Investigators

  • Michelle Trindade

  • Suellen C. Coelho

  • Mario F. Neves

  • Karin A. Jandeleit-Dahm

  • Pierre Paradis

  • Ernesto L. Schiffrin

Medical Centers

  • McGill Univ, Sir Mortimer B. Davis-Jewish General Hosp, Lady Davis Inst for Medical Res and Dept of Med, Vascular and Hypertension Res Unit, Montreal, QC, Canada

  • Baker IDI Heart & Diabetes Institute, Melbourne, Australia

  • Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

  • McGill Univ, Sir Mortimer B. Davis-Jewish General Hosp, Lady Davis Inst for Medical Res and Dept of Med, Vascular and Hypertension Res Unit, Montreal, QC, Canada

Locations

  • Brazil

  • Canada

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Vasodilation dysfunction

  • Type 1 diabetes mellitus

  • Coronary Artery Disease

  • Diabetes

Biomarkers

  • NADPH oxidase 1

  • Nicotinamide adenine dinucleotide phosphate oxidase

  • Nicotinamide-adenine dinucleotide phosphate oxidase 4

Drug/Treatment

  • Streptozotocin

  • Acetylcholine

Outcome

  • N/A

Study Design

  • adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved